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Background-—Atrial fibrillation is associated with higher mortality. Identification of causes of death and contemporary risk factors
for all-cause mortality may guide interventions.
Methods and Results-—In the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for
Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF) study, patients with nonvalvular atrial fibrillation were
randomized to rivaroxaban or dose-adjusted warfarin. Cox proportional hazards regression with backward elimination identified
factors at randomization that were independently associated with all-cause mortality in the 14 171 participants in the intention-
to-treat population. The median age was 73 years, and the mean CHADS2 score was 3.5. Over 1.9 years of median follow-up,
1214 (8.6%) patients died. Kaplan–Meier mortality rates were 4.2% at 1 year and 8.9% at 2 years. The majority of classified
deaths (1081) were cardiovascular (72%), whereas only 6% were nonhemorrhagic stroke or systemic embolism. No significant
difference in all-cause mortality was observed between the rivaroxaban and warfarin arms (P=0.15). Heart failure (hazard ratio
1.51, 95% CI 1.33–1.70, P<0.0001) and age ≥75 years (hazard ratio 1.69, 95% CI 1.51–1.90, P<0.0001) were associated with
higher all-cause mortality. Multiple additional characteristics were independently associated with higher mortality, with
decreasing creatinine clearance, chronic obstructive pulmonary disease, male sex, peripheral vascular disease, and diabetes
being among the most strongly associated (model C-index 0.677).
Conclusions-—In a large population of patients anticoagulated for nonvalvular atrial fibrillation, 7 in 10 deaths were
cardiovascular, whereas <1 in 10 deaths were caused by nonhemorrhagic stroke or systemic embolism. Optimal prevention and
treatment of heart failure, renal impairment, chronic obstructive pulmonary disease, and diabetes may improve survival.
Clinical Trial Registration-—URL: https://www.clinicaltrials.gov/. Unique identifier: NCT00403767. ( J Am Heart Assoc. 2016;5:
e002197 doi: 10.1161/JAHA.115.002197)
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P atients with atrial fibrillation (AF) are known to be atincreased risk of stroke, heart failure, and death.1–4 Oral
anticoagulation has been shown to improve survival of
patients with AF at risk of stroke.5–7 Although stroke or
systemic embolism accounts for only 10% of deaths in AF
patients,7–9 few if any therapies other than stroke prevention
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have been shown to improve survival in AF patients. Despite
the large proportion of AF mortality related to cardiovascular
events, rhythm control has not been shown to improve
survival in AF patients.10
Given the increasing frequency of AF and its association
with higher mortality, additional strategies to improve survival
are needed.11 The Rivaroxaban Once Daily Oral Direct Factor
Xa Inhibition Compared with Vitamin K Antagonism for
Prevention of Stroke and Embolism Trial in Atrial Fibrillation
(ROCKET AF) study was designed to compare the efficacy
and safety of rivaroxaban with warfarin for prevention of
stroke or systemic embolism in patients with AF at moderate
or high risk of stroke.12 The goal of this analysis was to
identify factors associated with all-cause mortality and to
describe cause-specific death to better inform potential
strategies for improving survival in patients with nonvalvular
AF.
Methods
The rationale and design of the ROCKET AF study have been
reported previously (NCT00403767).13 In summary, ROCKET
AF was an international, double-blind, double-dummy, ran-
domized noninferiority trial of fixed-dose rivaroxaban versus
adjusted-dose warfarin for the prevention of stroke or
systemic embolism. The study was funded by Johnson &
Johnson Pharmaceutical Research and Development and
Bayer HealthCare AG. The Duke Clinical Research Institute
coordinated the trial and performed the statistical analyses
for this study independent of the sponsors. An international
executive committee designed the study and took responsi-
bility for the accuracy and completeness of the analyses. All
appropriate national regulatory authorities and institutional
review boards at all study centers approved the study.
Definitions, End Points, and Baseline Variables
Patients were evaluated at a minimum of every 4 weeks
throughout the trial for study drug management, ascertain-
ment of adverse events, and surveillance for the primary end
points and other clinical events. The primary efficacy end
point in the ROCKET AF clinical trial was the composite of
stroke (ischemic or hemorrhagic) or systemic embolism.13 For
the purpose of this analysis, intention-to-treat data were used,
and the primary outcome of interest was all-cause mortality.
The secondary outcome of interest was cause-specific death.
All deaths were reviewed, and an independent clinical end
point committee blinded to treatment assignment adjudicated
causes of death.
Heart failure was defined as a clinical diagnosis of heart
failure or a left ventricular ejection fraction ≤35%. Hypertension
was defined as antihypertensive medications within 6 months
of enrollment, systolic blood pressure >140 mm Hg, or dias-
tolic blood pressure >90 mm Hg. The CHADS2 score was
calculated as 1 point for heart failure, hypertension, age
≥75 years, or diabetes and 2 points for stroke or transient
ischemic attack. Consistent with the method used in the
conduct of ROCKET AF, creatinine clearance was calculated
using a creatinine value measured at a site and the Cockcroft-
Gault formula.14
Vascular deaths included deaths from spontaneous bleed-
ing, myocardial infarction, stroke, heart failure, sudden death,
or arrhythmias. Patients who diedwithin 30 days of the onset of
a stroke were classified as having had a fatal stroke. Patients
who had a stroke and then died >30 days after the onset of the
stroke were classified based on the more immediate cause of
death. Sudden death was defined as witnessed or unwitnessed
death in a patient seen within 24 hours of death and known to
be asymptomatic at that time (Data S1).
Statistical Analysis
Baseline characteristics, stratified by survival, were summa-
rized numerically for categorical variables and as median
values with 25th and 75th percentiles for continuous
variables. Kaplan–Meier plots for all-cause death were
presented according to treatment allocation. Cox proportional
hazards regression was used to identify the factors at
randomization that were independently associated with the
occurrence of all-cause death in the 14 171 intention-to-treat
patients. All baseline variables recorded at randomization
were included in the model selection process, and covariates
were selected via backward elimination: age, sex, race,
ethnicity (Hispanic or non-Hispanic), region, heart rate, body
mass index, systolic blood pressure, diastolic blood pressure,
years since AF diagnosis, type of AF (persistent, paroxysmal,
recent onset), prior stroke or transient ischemic attack, heart
failure, hypertension, diabetes mellitus, creatinine clearance,
creatinine, peripheral arterial disease, chronic obstructive
pulmonary disease (COPD), prior gastrointestinal bleeding,
liver disease, alcohol use, obstructive sleep apnea, and left
bundle branch block. Associations are reported as hazard
ratios (HR) with 95% confidence intervals (CI). Following the
development of this model, an additional model was con-
structed with the inclusion of baseline medications, including
aspirin, prior vitamin K antagonist, and antiarrhythmic drug
therapy, as covariates. Predictive models were also generated
for cardiovascular death and sudden or unwitnessed death,
using the Fine-Gray method to account for competing risks.
All analyses were performed using SAS version 9.2 (SAS
Institute, Inc). The Duke institutional review board approved
this project, and all patients with data included in this analysis
signed informed consent.
DOI: 10.1161/JAHA.115.002197 Journal of the American Heart Association 2
Cause of Death in ROCKET AF Pokorney et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
D
ow
nloaded from
 http://ahajournals.org by on February 13, 2020
Results
Patient Characteristics
There were 14 171 patients in the intention-to-treat
population of ROCKET AF, with a median age of 73 years
and a mean CHADS2 score of 3.50.9. There was a
median follow-up of 1.9 years (25th, 75th percentiles: 1.4,
2.4 years) during which 1214 (8.6%) patients died, with an
event rate of 4.7 deaths per 100 patient-years. The Kaplan–
Meier mortality rate was 4.2% at 1 year and 8.9% at
2 years.
Among patients who died, the median age was 76 years
(25th, 75th percentiles: 69, 80 years), the mean CHADS2
score was 3.61.0, and 47.9% had prior stroke or transient
ischemic attack. Patients who died during follow-up were
older (aged 76 versus 72 years, P<0.0001), more frequently
male (66.1% versus 59.9%, P<0.0001), and more likely to have
a history of heart failure (70.3% versus 61.7%, P<0.0001) or
vascular disease (34.9% versus 22.2%) (Table 1). Patients who
died also were more likely to have lower creatinine clearance
by the Cockcroft-Gault formula (59 versus 68 mL/min,
P<0.0001) relative to patients who survived.
Table 1. Baseline Characteristics According to Survival
Characteristic Died During Follow-Up (n=1214) Alive (n=12 957) P Value*
Age, y 76 (69, 80) 72 (65, 78) <0.0001
Female sex 411 (33.9) 5194 (40.1) <0.0001
Region
Asia Pacific 168 (13.8) 1941 (15.0)
<0.0001
East Europe 407 (33.5) 5000 (38.6)
Latin America 203 (16.7) 1675 (12.9)
North America 285 (23.5) 2396 (18.5)
West Europe 151 (12.4) 1945 (15.0)
Body mass index, kg/m2 27.5 (24.3, 31.2) 28.3 (25.2, 32.0) <0.0001
Systolic pressure, mm Hg 130 (120, 140) 130 (120, 140) 0.0001
Diastolic pressure, mm Hg 80 (70, 84) 80 (70, 86) <0.0001
Heart rate, bpm 77 (68, 86) 76 (67, 86) 0.09
Creatinine clearance, Cockcroft/Gault, mL/min 59 (45, 77) 68 (53, 88) <0.0001
Type of atrial fibrillation
Persistent 1029 (84.8) 10 456 (80.7)
Paroxysmal 170 (14.0) 2320 (17.9) 0.001
New 15 (1.2) 180 (1.4)
CHADS2 score
Median (25th, 75th percentile) 3 (3, 4) 3 (3, 4) <0.0001
MeanSD 3.61.0 3.50.9
Aspirin 516 (42.5) 4668 (36.0) <0.0001
Vitamin K antagonists 740 (61.0) 8113 (62.6) 0.003
Thienopyridine 36 (3.0) 322 (2.5) 0.25
Hypertension 1105 (91.0) 11 719 (90.4) 0.72
Congestive heart failure 854 (70.3) 7997 (61.7) <0.0001
Diabetes 540 (44.5) 5107 (39.4) <0.0001
Stroke or TIA 582 (47.9) 6849 (52.9) 0.12
COPD 221 (18.2) 1260 (9.7) <0.0001
Vascular disease (PAD or MI) 424 (34.9) 2872 (22.2) <0.0001
Any alcohol use 370 (30.5) 4641 (35.8) <0.0001
Data are shown as n(%), median (25th, 75th percentiles), or medianstandard deviation. bpm indicates beats per minute; COPD, chronic obstructive pulmonary disease; MI, myocardial
infarction; PAD, peripheral artery disease; SD, standard deviation; TIA, transient ischemic attack.
*P values come from univariable Cox proportional hazards regression models.
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Classification of Cause of Death
Adjudicated cause-specific death rates are shown in Table 2
for the 1214 deaths, although 133 (11%) deaths were unable
to be classified. The majority of the classified deaths (1081)
were cardiovascular (72%), but only 6% of the classified
deaths were due to nonhemorrhagic stroke or systemic
embolism. Among the classified deaths in the trial, sudden or
unwitnessed death was the most frequent classification
(n=343, 32%), followed by death from heart failure (n=157,
15%). Nonvascular deaths accounted for 305 events (28%).
Intracranial hemorrhage was determined to be the cause of
death in 70 patients (0.3 deaths per 100 patient-years).
Among the 22 deaths related to extracranial hemorrhage
and 70 intracranial hemorrhage–related deaths, 6 (27%) and 8
(11%) of those patients, respectively, had a nonhemorrhagic
stroke within 1 year of death. There were 92 hemorrhage-
related deaths, and 14 (15%) of those patients had a
nonhemorrhagic stroke within 1 year of death.
Heart failure was associated with higher all-cause mortality
(HR 1.5, 95% CI 1.3–1.7, P<0.0001). Relative to patients
without heart failure, those with heart failure were more likely
to die from heart failure (0.8 versus 0.3 events per
100 patient-years, P<0.001) and sudden or unwitnessed
death (1.7 versus 0.8 events per 100 patient-years,
P<0.001). Patients without heart failure were more likely
than those with heart failure to die of intracranial hemorrhage
(0.4 versus 0.2 events per 100 patient-years, P=0.049).
Given the concerns regarding safety of oral anticoagulants
in elderly patients, the population was dichotomized based on
age ≥75 years. Age ≥75 years was associated with higher all-
cause mortality relative to age <75 years (HR 1.7, 95% CI
Table 2. Cause-Specific Mortality Among Classified Deaths in the Overall Population and According to Heart Failure Status,
Randomized Treatment, and Age
Subclassified Cause
of Death
Overall
(n=1081)
HF
(n=765)
No HF
(n=316)
HF
P Value
Age <75
(n=476)
Age ≥75
(n=605)
Age
P Value
Rivaroxaban
(n=523)
Warfarin
(n=558)
Treatment
P Value
Vascular 776 (3.0) 579 (3.7) 197 (2.0) <0.0001 363 (2.5) 413 (3.7) <0.0001 375 (2.9) 401 (3.1) 0.35
Myocardial infarction 38 (0.2) 31 (0.2) 7 (0.1) 0.014 16 (0.1) 22 (0.2) 0.07 18 (0.1) 20 (0.2) 0.75
Directly related to
revascularization
1 1 0 — 1 0 — 0 1 —
Nonhemorrhagic stroke 63 (0.2) 40 (0.3) 23 (0.2) 0.73 23 (0.2) 40 (0.4) 0.001 27 (0.2) 36 (0.3) 0.26
Intracranial hemorrhage 70 (0.3) 35 (0.2) 35 (0.4) 0.049 31 (0.2) 39 (0.4) 0.033 27 (0.2) 43 (0.3) 0.06
Pulmonary embolism 7 (0.03) 6 (0.04) 1 (0.01) 0.22 2 (0.01) 5 (0.1) 0.15 4 (0.03) 3 (0.02) 0.71
Noncoronary
atherosclerotic disease
7 (0.03) 4 (0.03) 3 (0.03) 0.84 2 (0.01) 5 (0.1) 0.15 2 (0.02) 5 (0.04) 0.27
Sudden/unwitnessed
death
343 (1.3) 263 (1.7) 80 (0.8) <0.0001 176 (1.2) 167 (1.5) 0.030 169 (1.3) 174 (1.4) 0.79
Dysrhythmia (other than
sudden death)
16 (0.1) 13 (0.1) 3 (0.03) 0.12 11 (0.1) 5 (0.1) 0.35 9 (0.1) 7 (0.1) 0.62
Heart failure/cardiogenic
shock
157 (0.6) 131 (0.8) 26 (0.3) <0.0001 65 (0.4) 92 (0.8) <0.0001 88 (0.7) 69 (0.5) 0.13
Extracranial hemorrhage 22 (0.1) 17 (0.1) 5 (0.1) 0.13 11 (0.1) 11 (0.1) 0.50 7 (0.1) 15 (0.1) 0.10
Other vascular 52 (0.2) 38 (0.2) 14 (0.1) 0.08 25 (0.2) 27 (0.2) 0.19 24 (0.2) 28 (0.2) 0.58
Nonvascular 305 (1.2) 186 (1.2) 119 (1.2) 0.95 113 (0.8) 192 (1.7) <0.0001 148 (1.2) 157 (1.2) 0.61
Accidental/trauma 15 (0.1) 9 (0.1) 6 (0.1) 0.94 9 (0.1) 6 (0.1) 0.83 5 (0.04) 10 (0.1) 0.21
Suicide 4 (0.02) 3 (0.02) 1 (0.01) 0.55 2 (0.01) 2 (0.02) 0.75 2 (0.02) 2 (0.02) 1.00
Respiratory failure 44 (0.2) 28 (0.2) 16 (0.2) 0.69 14 (0.1) 30 (0.3) 0.001 19 (0.2) 25 (0.2) 0.37
Liver failure 1 1 0 — 0 1 — 1 0 —
Infection/sepsis 97 (0.4) 62 (0.4) 35 (0.4) 0.54 35 (0.2) 62 (0.6) <0.0001 45 (0.4) 52 (0.4) 0.48
Renal failure 12 (0.1) 9 (0.1) 3 (0.03) 0.31 3 (0.02) 9 (0.1) 0.042 7 (0.1) 5 (0.04) 0.55
Malignancy 118 (0.5) 65 (0.4) 53 (0.5) 0.21 46 (0.3) 72 (0.7) <0.0001 63 (0.5) 55 (0.4) 0.46
Other nonvascular 14 (0.1) 9 (0.1) 5 (0.1) 0.85 4 (0.03) 10 (0.1) 0.042 6 (0.1) 8 (0.1) 0.59
Data are summarized as number of events (event rate per 100 patient-years of follow-up). P values come from univariable Cox proportional hazards regression models in which different
cause of death is censored. HF indicates heart failure.
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1.5–1.9, P<0.0001). There were several significant differ-
ences in the causes of death according to age <75 versus
≥75 years, including a higher prevalence of nonhemorrhagic
stroke (0.4 versus 0.2 events per 100 patient-years, P=0.001)
and sudden or unwitnessed death among patients <75 years
(1.5 versus 1.2 events per 100 patient-years, P=0.030).
Noncardiovascular causes of death such as malignancy and
infection were more common among patients aged ≥75
versus <75 years (0.7 versus 0.3 and 0.6 versus 0.2 events
per 100 patient-years, respectively, P<0.0001 for both).
Mortality by Treatment Strategy
The cumulative incidence of all-cause mortality was not
significantly different between the rivaroxaban and warfarin
arms (P=0.15) (Figure 1). There were 582 deaths (48% of all
deaths) on rivaroxaban and 632 deaths (52% of all deaths) on
warfarin (4.5 versus 4.9 events per 100 patient-years,
respectively; HR 0.92, 95% CI 0.82–1.03; P=0.15). There
was a trend toward lower incidence of death due to
intracranial hemorrhage with rivaroxaban compared with
warfarin (HR 0.63, 95% CI 0.39–1.02, P=0.06). There was
no significant difference in the associations between treat-
ment with rivaroxaban or warfarin and vascular or nonvascular
death (Table 3).
Factors Associated With All-Cause Mortality
The independent, significant predictors of increased mortality
were lower creatinine clearance, COPD, male sex, peripheral
vascular disease, older age, diabetes, heart failure, increased
heart rate, residence in Latin America, and prior stroke or
transient ischemic attack (Figure 2) (C-index 0.677). For each
10-mL/min decrease in creatinine clearance <60 mL/min,
the hazard of death increased by 25%. The presence of COPD
was associated with a 65% higher hazard of death. Alcohol
use, paroxysmal (versus persistent) AF, higher diastolic blood
pressure, and higher body mass index up to an index of 25
were associated with a lower risk of death. When baseline
medications were included as candidate variables, prior
vitamin K antagonist use was associated with lower mortality
(HR 0.77, 95% CI 0.68–0.87), whereas there was no
significant association between mortality and prior antiar-
rhythmic drug therapy or aspirin.
Factors Associated With Cause of Death
Vascular disease, heart failure, and diabetes were among the
factors most strongly associated with a higher likelihood of
cardiovascular death, with a 78%, 72%, and 44% increased
hazard of cardiovascular death, respectively (Figure 3)
(C-index 0.698). Female sex was associated with a lower
likelihood of cardiovascular death (HR 0.68, 95% CI 0.58–
0.80). Similarly for sudden or unwitnessed death, vascular
disease and heart failure were again among the factors most
strongly associated, with a 98% and 75% higher hazard of
sudden or unwitnessed death, respectively (Figure 4) (C-index
0.691). As with cardiovascular death, female sex was
A
ll-
ca
us
e 
m
or
ta
lit
y 
(%
)
0
2
4
6
8
10
12
14
Days
0 180 360 540 720 900
        7081
        7090
        6825
        6830
        6565
        6555
        4882
        4871
        3037
        3033
        1368
        1360
No. at risk
Warfarin
Rivaroxaban
p=0.152
Warfarin
Rivaroxaban
Figure 1. Cumulative incidence of all-cause mor-
tality in rivaroxaban vs warfarin arms in the
intention-to-treat population.
Table 3. Intention-to-Treat Treatment Effect of Rivaroxaban Versus Warfarin on Type of Death
Rivaroxaban (n=582) Warfarin (n=632) HR (95% CI) P Value
All-cause mortality 582 (4.5) 632 (4.9) 0.92 (0.82–1.03) 0.15
Vascular death 375 (2.9) 401 (3.1) 0.94 (0.81–1.08) 0.35
Nonvascular death 148 (1.2) 157 (1.2) 0.94 (0.75–1.18) 0.61
Death unknown cause 59 (0.5) 74 (0.6) 0.80 (0.57–1.12) 0.20
Sudden/unwitnessed death 169 (1.3) 174 (1.4) 0.97 (0.79–1.20) 0.79
CHF/shock cause of death 88 (0.7) 69 (0.5) 1.28 (0.93–1.75) 0.13
Malignancy cause of death 63 (0.5) 55 (0.4) 1.14 (0.80–1.64) 0.46
Intracranial hemorrhage death 27 (0.2) 43 (0.3) 0.63 (0.39–1.02) 0.06
Data are summarized as number of events (event rate per 100 patient-years of follow-up), unless otherwise indicated. CHF indicates congestive heart failure; HR, hazard ratio.
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associated with a lower likelihood of sudden or unwitnessed
death.
Discussion
The use of oral anticoagulation reduces all-cause mortality in
AF patients,5 but a better understanding of risk factors for
mortality among anticoagulated AF patients is necessary to
identify additional interventions to improve care for these
patients. This analysis of the ROCKET AF data demonstrates
the high rate of aggregated cardiovascular death, which
occurs 2.1 times more often than stroke, 4.5 times more
often than myocardial infarction, and 1.4 times more often
than major bleeding. The majority of deaths are not related to
stroke or systemic embolism. There are no differences in
event rates of any type of death among patients treated with
rivaroxaban or warfarin. In addition to patients with pulmonary
and renal disease, many of the patient characteristics
associated with higher mortality rates are traditional cardio-
vascular risk factors.
The 1- and 2-year mortality rates were 4% and 9%,
respectively, with 4.7 deaths per 100 patient-years. The
primary end point in ROCKET AF was stroke or systemic
embolism, and in the intention-to-treat analysis, the primary
end point occurred 2.1 and 2.4 times per 100 patient-years in
the rivaroxaban and warfarin populations, respectively.12 Any
major bleeding occurred 3.6 and 3.4 times per 100 patient-
years for rivaroxaban and warfarin, respectively. The mortality
rates in ROCKET AF were lower than the previously published
1-year mortality rate of 23% for patients (mean age 73 years)
in Olmsted County, Minnesota, with new-onset AF between
1980 and 2000.15 Mortality rates in the current study were
also lower than the 1- and 2-year mortality rates of 20% and
28%, respectively, for an older Medicare population (mean age
80 years) with newly diagnosed AF; however, similar to the
findings in ROCKET AF, death was the most common event
within 2 years of diagnosing AF.16 In the Medicare population,
death was >3 times more common than heart failure and
occurred 8 times more frequently than stroke or gastroin-
testinal bleed. The Danish Registry of AF patients treated with
Figure 2. Factors associated with all-cause mortality, with points to the left of unity being associated with
lower likelihood of all-cause mortality and points to the right of unity being associated with higher likelihood
of all-cause mortality. C-index 0.677 (25th, 75th percentiles: 0.661, 0.693). AF indicates atrial fibrillation;
BMI, body mass index; BP, blood pressure; COPD, chronic obstructive pulmonary disease; HR, hazard ratio;
TIA, transient ischemic attack.
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warfarin or dabigatran 150 mg is another example of death
being more common than stroke, major bleeding, or myocar-
dial infarction in general practice outside of clinical trials.17
Oral anticoagulants remain an important prevention strat-
egy in AF patients, and nonadherence is associated with
increased risk of stroke or death.18 In fact, oral anticoagu-
lation is the only intervention shown in randomized trials to
improve all-cause survival in patients with nonvalvular AF. A
meta-analysis of randomized controlled trials showed that
warfarin had 26% relative risk reduction (95% CI 3–43%) in all-
cause mortality compared with placebo.5 It may be that
treatment with an oral anticoagulant matters more for
mortality in AF patients than other baseline factors, and the
fact that all patients were treated with an oral anticoagulant
may partially explain the modest C-index of 0.677 for the
mortality model.
In our analysis of patients being prescribed oral antico-
agulants in ROCKET AF, 1 in 20 patients died from stroke
or systemic embolism, whereas more than half of the overall
deaths were from other cardiovascular causes. These
proportions of cause-specific death were similar to those
reported in the Atrial Fibrillation Follow-up Investigation of
Rhythm Management (AFFIRM) trial, in which 11% of deaths
were vascular and 39% of the deaths were nonvascular
cardiac deaths.8 In AFFIRM, there were no statistically
significant differences in rates of vascular or cardiac deaths
between rate- and rhythm-control strategies. Similar findings
of 10% vascular death and 37% cardiac death were seen in
the clinical trial comparison of dabigatran and warfarin; 7%
of classified deaths in the dabigatran study were due to
stroke or systemic embolism, and this was similar to the 6%
seen in this analysis, despite the fact that the mean CHADS2
score of patients who died was higher in our study (3.6
versus 2.5).9 The most common cause of noncardiovascular
death was malignancy in our study (11%) and in the
dabigatran analysis (14%).9
Patients with AF tend to be older and have multiple
comorbid cardiovascular diseases that could be lethal and
Figure 3. Factors associated with cardiovascular death, with points to the left of unity being associated
with lower likelihood of cardiovascular death and points to the right of unity being associated with higher
likelihood of cardiovascular death. C-index 0.698. AF indicates atrial fibrillation; BMI, body mass index; BP,
blood pressure; COPD, chronic obstructive pulmonary disease; HR, hazard ratio; TIA, transient ischemic
attack.
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require appropriate prevention and treatment. Renal disease
and pulmonary disease were among the factors most strongly
associated with all-cause mortality. Patients with stage 3
chronic kidney disease in our analysis had a 25% increase in
the hazard of death associated with a 10-mL/min decrease in
creatinine clearance. Cardiovascular disease factors, such as
peripheral vascular disease, diabetes, and heart failure, were
also associated with all-cause mortality. This emphasizes the
importance of treating all cardiovascular conditions in AF
patients. Reductions in weight and blood pressure along with
better glycemic and lipid management have been shown to
improve arrhythmia-free survival after AF ablation in the
Aggressive Risk Factor Reduction Study for Atrial Fibrillation
and Implications for the Outcome of Ablation (ARREST-AF)
study.19 Despite the evidence for risk factor management, it
has been demonstrated previously that the minority of AF
patients receive guideline-recommended therapies for their
comorbid cardiovascular conditions, with nearly 60% of AF
patients with peripheral vascular disease, diabetes, and heart
failure not receiving all guideline-based treatment.20
Sudden or unwitnessed death was the most common
cause of death, seen in 1 in 3 deaths. Heart failure was
among the strongest predictors of sudden or unwitnessed
death (HR 1.75, 95% CI 1.35–2.26). A similar finding was
noted in the dabigatran analysis, in which sudden death
accounted for 20% of deaths, and heart failure was the
strongest predictor, with a HR of 2.24 (95% CI 1.75–2.87).9
An analysis of the Oregon Sudden Unexpected Death Study
identified a high prevalence of AF in cases of sudden cardiac
death relative to controls (27% versus 18%, P=0.0001), but
further analyses demonstrated that heart failure at least
partially explained the association between AF and sudden
cardiac death.21
Clinical Implications
These data have several important clinical implications.
Patients with AF are most commonly dying from cardiovas-
cular conditions. This emphasizes the importance of following
the general cardiology guidelines of care in AF patients.
Patients with diabetes should be treated with angiotensin-
converting enzyme inhibitors or angiotensin receptor block-
ers, and heart failure patients should be on optimal medical
therapy. Patients with AF should be monitored closely for the
development of comorbidities, such as heart failure, periph-
eral vascular disease, COPD, diabetes, and hypertension.
Early detection of these conditions and aggressively optimiz-
ing treatment regimens may improve mortality in AF patients
on anticoagulation. Some data show that AF ablation may
treat heart failure in patients with AF, and further research is
Figure 4. Factors associated with sudden or unwitnessed death, with points to the left of unity being
associated with lower likelihood of sudden or unwitnessed death and points to the right of unity being
associated with higher likelihood of sudden or unwitnessed death. C-index 0.691. BP indicates blood
pressure; COPD, chronic obstructive pulmonary disease; HR, hazard ratio.
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needed on the effect of AF ablation on mortality in heart
failure patients.22,23 Future research should be focused on
improving mortality in patients with AF and COPD, diabetes,
peripheral vascular disease, and heart failure because these
modifiable conditions are all associated with higher mortality
with AF.
Limitations
Several important limitations must be kept in mind when
considering our results. The generalizability of these results
may be limited because this was a clinical trial population.
Patients with the highest risk of mortality, such as those with
active malignancy, were not included in ROCKET AF. Never-
theless, the ROCKET AF trial included patients with a greater
number of comorbidities by CHADS2 score relative to the
other trials comparing non–vitamin K oral anticoagulants with
warfarin.24–26 The multivariable models were established
based on baseline demographics and characteristics, and
they may not have reflected patients’ comorbidities at the
time of death. Spectrums of disease severity exist for
peripheral vascular disease, COPD, diabetes, and heart failure;
however, for the purposes of modeling, these diseases were
treated as binary events. Data on treatment regimens for the
comorbidities were not available and were not incorporated
into the model. Although multivariable adjustment was
performed, there may be significant, unmeasured confounding
in the comparison between patients who died and those that
lived. A large percentage of the classified deaths (32%) were
sudden or unwitnessed, and autopsy data were not frequently
available for event adjudication. It is possible that these cases
resulted in underestimation of the incidence of death related
to stroke.
Conclusions
Overall, >1 in 2 deaths in AF patients treated with oral
anticoagulation were cardiovascular deaths unrelated to
stroke or systemic embolism. In a large population of patients
with nonvalvular AF, the strongest predictors of mortality
were reduced renal function, COPD, male sex, peripheral
vascular disease, and age. Cardiovascular disease risk factor
modification needs to be emphasized for all AF patients,
including optimal medical therapy to treat heart failure,
smoking cessation to prevent COPD, and blood pressure
control and angiotensin-converting enzyme inhibitors or
angiotensin receptor blockers for diabetic patients to prevent
renal dysfunction. Continued investigations of the mortality
impact of management of nonvalvular AF should focus on
patients with a high burden of comorbidities, including
patients with concomitant renal and pulmonary disease.
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